A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C. (Q42283380)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

title

A pilot study of triple therapy with telaprevir, peginterferon and ribavirin for elderly patients with genotype 1 chronic hepatitis C (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

1 reference

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

10

Hiromitsu Kumada

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

3

Fumitaka Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

7

Masahiro Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

5

Yoshiyuki Suzuki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

2

Norio Akuta

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

4

Hitomi Sezaki

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

9

Satoshi Saitoh

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

8

Mariko Kobayashi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

author name string

Tasuku Hara

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

language of work or name

1 reference

16 July 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

Journal of Medical Virology

5 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

volume

85

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

5 March 2020

page(s)

1746-1753

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy.

5 March 2020

cites work

1 reference

Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.

21 January 2018

1 reference

Amino acid substitution in HCV core region and genetic variation near the IL28B gene affect viral dynamics during telaprevir, peginterferon and ribavirin treatment

21 January 2018

1 reference

Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection

21 January 2018

1 reference

New direct-acting antivirals' combination for the treatment of chronic hepatitis C.

21 January 2018

1 reference

IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C

21 January 2018

1 reference

Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection

21 January 2018

1 reference

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

21 January 2018

1 reference

Efficacy of peginterferon-alpha-2b plus ribavirin in patients aged 65 years and older with chronic hepatitis C.

21 January 2018

1 reference

Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

21 January 2018

1 reference

Necessities of interferon therapy in elderly patients with chronic hepatitis C.

21 January 2018

1 reference

Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group

21 January 2018

1 reference

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C.

21 January 2018

1 reference

Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis

21 January 2018

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan

21 January 2018

1 reference

Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy

21 January 2018

1 reference

Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.

21 January 2018

1 reference

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection

21 January 2018

1 reference

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy

21 January 2018

1 reference

Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis

21 January 2018

1 reference

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population

21 January 2018

1 reference

A high-throughput SNP typing system for genome-wide association studies

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/JMV.23673

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23861088%20AND%20SRC:MED&resulttype=core&format=json

release_coyx6jx43zcovod6h7ykqkga34

5 March 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/coyx6jx43zcovod6h7ykqkga34

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference